All In MedTech

Device Trial Radar · NCT07946224

Comparison of Breast Acoustic CT and Automated Breast Ultrasound in Women With Unilateral Untreated Breast Cancer

Comparison of the Diagnostic Accuracy of Bilateral Whole Breast Ultrasound Using QT Imaging and Invenia Automated Breast Ultrasound (ABUS) [GE Healthcare] in Women With Unilateral Untreated Current Breast Cancer.

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Jan 2029

Study completion Jan 2029

Sponsor

Lead sponsor
Stanford UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
QT Imaging Holdings, Inc.
First posted
Nov 18, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study addresses an unmet need to improve the diagnostic accuracy of: 1. supplemental breast cancer screening with whole breast US and 2. the evaluation of disease extent in women with newly diagnosed breast cancer.

Conditions

  • Breast Cancer

Interventions

  • QT Scanner: Quantitative Transmission Ultrasound Breast Imaging SystemDevice

    QT: The scanner is an FDA-cleared imaging technology that uses transmission ultrasound to generate quantitative maps of breast tissue properties (e.g., speed of sound, absorption) as well as provides reflection ultrasound images. It is a non-invasive, non-ionizing imaging modality and does not involve administration of a drug or biologic. Each participant will undergo one (1) imaging examination using the QT Scanner for comparison with images obtained using automated breast ultrasound (ABUS)

  • ABUS: Invenia™ ABUS, Invenia Automated Breast Ultrasound System, ABUS, GE ABUSDevice

    ABUS is FDA-approved for both supplemental breast cancer screening in women with radiographically dense breast tissue, and for diagnostic breast ultrasound imaging. Each participant will undergo one ABUS imaging examination for comparison with images obtained using the investigational QT Scanner.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Additional Breast Cancer Lesions DetectedTime frame: Baseline
  2. BI-RADS AssessmentTime frame: Baseline
  3. Numerical Likelihood of MalignancyTime frame: Baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Palo Alto, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.